ALC stays on investors' radar due to its Vision Care arm's performance and contributions from new products despite macro risks and stiff competition.

Shares of Lupin are set to be in focus after it received US FDA approval for its generic Loteprednol Etabonate Ophthalmic Gel ...

LENZ Therapeutics' aceclidine outshines Vuity for presbyopia with better safety and duration. Click for LENZ's market ...

Lupin today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New ...

A novel eye drop formulation shows antioxidant effects and may protect corneal epithelial cells, according to research presented at AOA 2025.